BESSE, Lenka, Andrej BESSE, Max MENDEZ-LOPEZ, Kateřina VAŠÍČKOVÁ, Miroslava SEDLÁČKOVÁ, Petr VAŇHARA, Marianne KRAUS, Jurgen BADER, Renan B. FERREIRA, Ronald K. CASTELLANO, Brian K. LAW and Christoph DRIESSEN. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2019, vol. 104, No 9, p. 415-419. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.207704.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis
Authors BESSE, Lenka (756 Switzerland, guarantor), Andrej BESSE (756 Switzerland), Max MENDEZ-LOPEZ (756 Switzerland), Kateřina VAŠÍČKOVÁ (203 Czech Republic, belonging to the institution), Miroslava SEDLÁČKOVÁ (203 Czech Republic, belonging to the institution), Petr VAŇHARA (203 Czech Republic, belonging to the institution), Marianne KRAUS (756 Switzerland), Jurgen BADER (756 Switzerland), Renan B. FERREIRA (840 United States of America), Ronald K. CASTELLANO (840 United States of America), Brian K. LAW (840 United States of America) and Christoph DRIESSEN (756 Switzerland).
Edition Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2019, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.116
RIV identification code RIV/00216224:14110/19:00110883
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3324/haematol.2018.207704
UT WoS 000483996100008
Keywords in English metabolic switch; proteasome inhibitor; multiple myeloma
Tags 14110517, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/10/2019 09:30.
Abstract
Proteasome inhibitors (PI) have evolved as the central backbone of treatment for multiple myeloma (MM), with first-in-class bortezomib and second- and third-generation PI, carfilzomib and ixazomib, having been approved for this indication. Proteasome inhibition disrupts the unfolded protein response to resolve excessive endoplasmic reticulum stress, but also leads to massive metabolic changes manifested by the induction of amino acid biosynthesis, an anti-oxidant response, lipogenesis and an increase in protein folding. In this sense, PI represent a unique class of drugs targeting cancer cell metabolism by affecting the balance between protein biosynthesis, folding and destruction. However, the adaptive changes in MM cell metabolism may provide the basis of resistance to PI, as high glycolytic activity or rewiring glucose metabolism is associated with bortezomib resistance in MM.
PrintDisplayed: 4/8/2024 14:20